After Kite Pharma stuns analysts with news of a death in lead CAR-T study, safety questions sour launch forecast
There may never have been a right way for Kite Pharma to announce that a patient in one of its CAR-T studies died from cerebral edema — but waiting more than a week and then bringing it up on the quarterly call with analysts definitely wasn’t the way to go. That route seems to have only brightened the glaring spotlight that immediately swiveled over to company execs as they tried to explain, and downplay, the death.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.